We had the continuation yesterday only to fail later in the day. It is looking that this bounce might only be setting up another leg lower but it is clearly too early to have any confidence. That being said I would at least be prepared in case there is another leg lower as it would […]
August 13 Biotech Update
We had our reversal yesterday that I talked about, although I had my doubts for a little while. That is probably enough to get some buying interest barring additional negative macro issues. China did a third round of devaluations but I suspect it will have less of an effect on the market given it is […]
August 12 Biotech Update
Essentially more of the same yesterday and into the morning today. At the very least, I think we are probably close to a bounce and would not be surprised to see a gap lower this morning and then a rally into the green by the end of the day. It is amazing that the market […]
August 11 Biotech Update
Not a lot of biotech news again but macro is creeping back into the discussion with China devaluing their currency. Who knows the pin action this will have on the sector as it could mean global growth is too slow and biotechs are then the best growers. It could mean that it will trigger more […]
August 10 Biotech Update
We are getting a spurt of IO collaborations this morning but no major news or M&A. After the sell off Friday (and come back), I would not be surprised to see that positive momentum continue this morning. Worst case scenario would be early strength and then faded all day. Best case, obviously, would be early […]
August 7 Biotech Update
I am not able to write for a couple of days and the market goes to crap, I figured you all would be able to keep down the fort better than that. As much as it seems like a beating (it is) I do not think we are seeing the bubble burst (of course, I […]
August 4 Biotech Update
Looks like the sector was saving the fireworks for today with a lot more news. The reaction so far seems a little tepid given the positives but it is early and I think some are a little worried about the broader market. The collapse in oil may unfortunately signal a return to the macro market […]
August 3 Biotech Update
It is a pretty tame start to the week. I am a little surprised given that there seemed to be some bullish late Friday price and option action with concomitant rumors. It seemed like the week would start with a bang but we pretty much had crickets. Given the role that M&A has played in […]
July 31 Biotech Update
Not a lot of news so I want to round out a couple of issues this morning and close it out for the week. I am finding it more and more difficult to note whether the sector is strong or weak, which makes me think the best description is choppy. Overall it seems like modest […]
July 30 Biotech Update
The sector is pretty weak, which is a continuation of the past couple of days. It is not immediately clear to me the reason for the weakness as earnings have been almost universally good (notable exception being BIIB). Given the lack of news, I will spend today brainstorming some ideas for the weakness as well […]
July 29 Biotech Update
The sector was a strong performer after the bell but it did not seem to last long. The sector should be strong given the bulk of the earnings but I cannot shake the feeling that sentiment has slipped. Perhaps it is the broader market acting as a drag but I am not convince the sector […]
July 28 Biotech Update
The sector looked like it would be off to a good start but it faded quickly. I would still argue that any movement before the GILD earnings can be quickly changed, so the trading action tomorrow is much more important than anything today. Not a ton of major news but a decent amount of tidbits, […]
July 27 Biotech Update
The market looks bad and it is bringing down the sector although I think BIIB has done a pretty good job at reversing some bullish biotech sentiment. That being said the sector might be outperforming the broader market a little as there was a nice big deal announced this morning. When all is said and […]
BioBlast Pharma: an under the radar ultra-rare disease company
Bio Blast Pharma Ltd. (ORPN) – Nasdaq BioBlast Pharma (ORPN) is a clinical-stage biotech company, focused on treatments for rare and ultra-rare diseases, especially genetic and metabolic diseases. The company has three diversified platforms currently address five different diseases. The platforms include Cabaletta, which is a platform for diseases characterized by mutated proteins; BBrm platform is a […]
July 24 Biotech Update
Unlike earlier this week where bad news was shrugged off, it looks like we are going to see selling on the bad news. This pullback should eventually generate nice bargains if it picks up steam but it might not be an immediate buy the dip as earning have been relatively mixed, so money may be […]
July 23 Biotech Update
A good start to the day with earnings almost universally beats and raises. Given the strength the sector showed yesterday, this should move the group higher and increase expectations for those companies that have not yet reported but perhaps we are in an opposite mode and will sell good news and buy bad. 1. BMY […]
July 22 Biotech Update
The sector is a little weak this morning, which is to be expected but not nearly as weak as I thought it would be going into the open. There has been some negative news (or mixed depending on your view) and I figured this would weigh more heavily on the group. It is obviously still […]
July 21 Biotech Update
The sector was green again yesterday and this morning but it does not seem to be a broad based move. The small caps appear to be underperforming and among the large caps it seems isolated to CELG with AMGN and GILD being relatively weak. This narrowing of the move tells me that we are much […]
July 20 Biotech Update
There is some news this morning but nothing that in and of itself is likely to move the sector. On the other hand, the news has generally been positive, so there is nothing to change the momentum to the upside. It is nice to see a week begin without a major macro discussion. Perhaps this […]
July 17 Biotech Update
I leave town and the sector runs to new all-time highs and I come back and there is a pullback. Perhaps the market is trying to tell me something. It is not surprising to see a pause even a pullback but I also think people were underinvested expecting a deeper sell-off, so I am not […]
